CRDF vs. ATXS

In the year-to-date period, CRDF achieves a -4.38% return, which is significantly higher than ATXS's -21.48% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Cardiff Oncology, Inc. (CRDF) and Astria Therapeutics, Inc. (ATXS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CRDF Sharpe Ratio is 0.99, which is higher than the ATXS Sharpe Ratio of -0.91. The chart below compares the historical Sharpe Ratios of CRDF and ATXS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CRDF nor ATXS has paid dividends to shareholders.

The maximum CRDF drawdown since its inception was -99.96%, roughly equal to the maximum ATXS drawdown of -99.72%. Use the drawdown chart below to compare losses from any high point for CRDF and ATXS. For additional features, visit the drawdowns tool.

Cardiff Oncology, Inc. (CRDF) has a higher volatility of 21.80% compared to Astria Therapeutics, Inc. (ATXS) at 12.42%. This indicates that CRDF's price experiences larger fluctuations and is considered to be riskier than ATXS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Cardiff Oncology, Inc. and Astria Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.